Eli Lilly reiterated retatrutide’s phase 3 strength for obesity with type 2 diabetes, framing TRIUMPH-2 as a major milestone for the weight-loss drug class. In the study, patients receiving the highest dose saw average body-weight loss exceeding 20%, alongside improvements in blood sugar and cardiometabolic risk factors. The readout highlighted large absolute weight reductions across dose arms and substantial proportions of patients reaching obesity normalization by study end, according to Lilly. The company also pointed to reductions in cholesterol and blood pressure, outcomes relevant to cardiovascular risk in a population with established metabolic disease. For competitors, the message is clear: Lilly is targeting not only weight change but also broader metabolic benefits in the same pivotal program, raising the bar for what future next-generation agents must demonstrate.